Reports Q2 revenue $99.0M, consensus $95.2M. The company said, “We are committed to enhancing surgeon confidence and practice implementation, growing the category and seizing market share throughout the business cycle. For our surgeon customers globally, our EVO ICL technology is increasingly instrumental in enhancing their offerings, market competitiveness and practice economics. As a result, our commercial momentum is accelerating – as evidenced by these latest financial results, which are due to execution against our vital few strategic priorities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STAA:
- STAA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Staar Surgical price target raised to $53 from $46 at BTIG
- Staar Surgical downgraded to Underweight from Equal Weight at Morgan Stanley
- Staar Surgical Enhances Governance and Growth Strategy
- Staar Surgical Hosts Investor Presentation Series